Akouos, Inc. (AKUS)
| Market Cap | 473.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -48.60M |
| Shares Out | 34.40M |
| EPS (ttm) | -2.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $14.00 |
| Previous Close | $13.76 |
| Change ($) | 0.24 |
| Change (%) | 1.74% |
| Day's Open | 13.91 |
| Day's Range | 13.63 - 14.43 |
| Day's Volume | 110,904 |
| 52-Week Range | 13.16 - 30.67 |
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...
- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF
Akouos (AKUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassesse...
About AKUS
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibul... [Read more...]
| Industry Biotechnology | IPO Date Jun 26, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol AKUS |
Analyst Forecasts
According to 4 analysts, the average rating for Akouos stock is "Strong Buy." The 12-month stock price forecast is 31.67, which is an increase of 126.21% from the latest price.